Emeryville, California, November 20, 2023 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it will present at the sixth annual Evercore ISI HealthCONx conference Tuesday, November 28 exist 4:40 p.m. (ET).
The presentation will be conducted via a live webcast and can be accessed through the Events and Presentations page of the Investors section of the Company’s website at https://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The company has two commercial products, HEPLISAV-B® Vaccine (Hepatitis B vaccine (recombinant), adjuvant), already available in the United States, the European Union and Great Britain For the prevention of infection caused by all known hepatitis B virus subtypes in adults 18 years of age and older, plus CpG 1018® Adjuvants currently used in multiple adjuvants for COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant into clinical programs for adjuvant vaccines against herpes zoster and Tdap as a first-line vaccine adjuvant, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and general influenza .For more information about our marketing products and development pipeline, please visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.
For investors/media:
Paul Cox
(email protected)
510-665-0499
Nicole Arndt
(email protected)
510-665-7264
SOURCE Dynavax Technologies
